Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25785125 | 0.89 | CYP1A2 (0.30) | CYP1A2 | |
| SCHEMBL21323268 | 0.87 | DPP4 (0.30) | — | |
| SCHEMBL19122108 | 0.87 | DPP4 (0.30) | — | |
| SCHEMBL25125594 | 0.81 | — | — | |
| SCHEMBL18806109 | 0.81 | SOS1 (0.35) | CYP1A2SOS1SOS2 | |
| SCHEMBL27275379 | 0.74 | SOS1 (0.37) | CYP1A2SOS1SOS2 | |
| SCHEMBL25071206 | 0.73 | SOS1 (0.40) | SOS1SOS2 | |
| SCHEMBL13886937 | 0.72 | DPP4 (0.34) | — | |
| SCHEMBL19440604 | 0.72 | — | — | |
| SCHEMBL21210666 | 0.71 | GNAI3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022261210-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-02-11 | — | — | US | disclosed |
| US-10793563-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
| US-20190233411-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233411-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CYP1A2 3059/4885SOS1 4238/4885SOS2 3072/4885 |
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CYP1A2 3059/4885SOS1 4238/4885SOS2 3072/4885 |
| US-10793563-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, GCGR | CYP1A2 3059/4885SOS1 4238/4885SOS2 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.